Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Modified-Release Drug Delivery Systems: Drug Release Characteristics01:22

Modified-Release Drug Delivery Systems: Drug Release Characteristics

231
Drug release from modified-release dosage forms is designed to achieve specific therapeutic effects by controlling the rate and extent of drug release. The classification of these drug release systems is based on key pharmacokinetic assumptions: drug disposition follows first-order kinetics, drug release is the rate-limiting step in absorption, and the released drug is rapidly and completely absorbed.There are four major models of drug release patterns. The first model is the slow zero-order...
231
Modified-Release Drug Delivery Systems: Rate-Programmed II01:19

Modified-Release Drug Delivery Systems: Rate-Programmed II

108
Rate-programmed drug delivery systems release drugs in a controlled manner to maintain therapeutic levels. Three main designs include reservoir, matrix, and hybrid systems.Reservoir systems consist of a drug core enclosed within a membrane that controls drug release. In non-swelling reservoir systems, polymers like ethyl cellulose or polymethacrylates are used. These do not hydrate in aqueous media and control release through membrane thickness, porosity, or insolubility. This type includes...
108
Modified-Release Drug Delivery Systems: Influencing Factors01:20

Modified-Release Drug Delivery Systems: Influencing Factors

179
Modified-release drug delivery systems are designed to optimize the therapeutic effect of drugs by minimizing side effects, reducing the dosage required, and controlling drug release to align with pharmacokinetic and pharmacodynamic needs. The system depends on two key factors: the drug's release from the formulation and its movement through the body to the target site. Unlike conventional dosage forms, where absorption is the limiting step, the rate of drug release is the key determinant in...
179
Modified-Release Drug Delivery Systems: Rate-Programmed I01:22

Modified-Release Drug Delivery Systems: Rate-Programmed I

152
Rate-programmed drug delivery systems (DDS) are designed to release drugs at specific, controlled rates to maintain consistent therapeutic levels. These systems are categorized based on their release mechanisms, including dissolution-controlled DDS, diffusion-controlled DDS, and combined dissolution-diffusion-controlled DDS.In dissolution-controlled DDS, the release rate depends on the slow dissolution of the drug itself or the surrounding matrix. Drugs with inherently slow dissolution rates,...
152
Modified-Release Drug Delivery Systems: Stimuli-Activated01:30

Modified-Release Drug Delivery Systems: Stimuli-Activated

146
Stimuli-activated drug delivery systems are designed to release drugs in response to specific physical, chemical, or biological stimuli. These systems often utilize hydrogels—three-dimensional, hydrophilic polymer networks capable of swelling in aqueous environments and retaining significant fluid volumes. Upon exposure to particular stimuli, these hydrogels undergo structural transitions that allow the embedded drug to be released. Due to this adaptive behavior, such systems are also...
146
Oral Drug Delivery Systems: Continuous-Release Systems01:26

Oral Drug Delivery Systems: Continuous-Release Systems

268
Continuous-release drug delivery systems offer a strategic approach to maintaining therapeutic drug levels over extended periods following oral administration. By modulating the release rate of active pharmaceutical ingredients, these systems minimize fluctuations in plasma concentrations, which enhances clinical efficacy and reduces the need for frequent dosing. Such characteristics make them particularly advantageous in managing chronic diseases where patient adherence and stable drug...
268

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Targeting the Energy-Coupling Factor Transporters: A Novel Antibiotic Drug Target in <i><i>Streptococcus pneumoniae</i></i>.

Journal of medicinal chemistry·2026
Same author

Defined Nylon Oligomers Enable Mechanistic Insight Into Enzymatic Polyamide Depolymerization.

ChemSusChem·2026
Same author

Hit-to-Lead Optimization of Energy-Coupling Factor (ECF) Transporter Inhibitors as Novel Antibiotic.

Journal of medicinal chemistry·2026
Same author

Cytochrome P450-Mediated Metabolism of Antimycobacterial <i>N</i>α-Aroyl-<i>N</i>-aryl-phenylalanine Amides.

ACS infectious diseases·2026
Same author

Psychosis after weight loss during continuous subcutaneous foslevodopa/foscarbidopa therapy - a case series.

Journal of movement disorders·2026
Same author

Identification of DksA as a novel pro-inflammatory mediator of <i>Pseudomonas aeruginosa</i> under conditions mimicking chronic cystic fibrosis lung infection.

Virulence·2026

Related Experiment Video

Updated: Apr 19, 2026

Solubility of Hydrophobic Compounds in Aqueous Solution Using Combinations of Self-assembling Peptide and Amino Acid
05:08

Solubility of Hydrophobic Compounds in Aqueous Solution Using Combinations of Self-assembling Peptide and Amino Acid

Published on: September 20, 2017

17.9K

Combinatorial screening for specific drug solubilizers with switchable release profiles.

Sebastian Wieczorek1, Sara Vigne, Tiziana Masini

  • 1Laboratory for Organic Synthesis of Functional Systems, Department of Chemistry, Humboldt-Universität zu Berlin, Brook-Taylor-Str. 2, D-12489, Berlin, Germany.

Macromolecular Bioscience
|January 6, 2015
PubMed
Summary
This summary is machine-generated.

New polymer-block-peptide conjugates enhance drug solubility and enable controlled release. This versatile platform offers a promising strategy for delivering hydrophobic drugs via sequence-specific peptide interactions and cleavable linkers.

Keywords:
PEGdrug deliverydrug formulationpeptidestimuli responsive

More Related Videos

High-throughput Screening for Chemical Modulators of Post-transcriptionally Regulated Genes
09:44

High-throughput Screening for Chemical Modulators of Post-transcriptionally Regulated Genes

Published on: March 3, 2015

10.1K
High-throughput Identification of Synergistic Drug Combinations by the Overlap2 Method
07:51

High-throughput Identification of Synergistic Drug Combinations by the Overlap2 Method

Published on: May 21, 2018

13.0K

Related Experiment Videos

Last Updated: Apr 19, 2026

Solubility of Hydrophobic Compounds in Aqueous Solution Using Combinations of Self-assembling Peptide and Amino Acid
05:08

Solubility of Hydrophobic Compounds in Aqueous Solution Using Combinations of Self-assembling Peptide and Amino Acid

Published on: September 20, 2017

17.9K
High-throughput Screening for Chemical Modulators of Post-transcriptionally Regulated Genes
09:44

High-throughput Screening for Chemical Modulators of Post-transcriptionally Regulated Genes

Published on: March 3, 2015

10.1K
High-throughput Identification of Synergistic Drug Combinations by the Overlap2 Method
07:51

High-throughput Identification of Synergistic Drug Combinations by the Overlap2 Method

Published on: May 21, 2018

13.0K

Area of Science:

  • Bioconjugation Chemistry
  • Drug Delivery Systems
  • Materials Science

Background:

  • Hydrophobic small molecule drugs often suffer from poor water solubility, limiting their therapeutic efficacy.
  • Developing effective drug delivery systems is crucial for improving bioavailability and targeted delivery of poorly soluble compounds.

Purpose of the Study:

  • To design and synthesize polymer-block-peptide conjugates for enhanced water solubility of hydrophobic drugs.
  • To achieve sequence-specific solubilization and switchable drug release using peptide libraries and disulfide linkers.

Main Methods:

  • Employed a combinatorial strategy to create peptide libraries integrated into polymer-block-peptide conjugates.
  • Incorporated a disulfide linker moiety for controlled drug release.
  • Utilized the photosensitizer m-THPC as a model hydrophobic drug cargo.

Main Results:

  • Demonstrated sequence-specific solubilization of hydrophobic drugs by the designed bioconjugates.
  • Achieved switchable drug release profiles, triggered by reductive cleavage of the disulfide linker.
  • Validated the potential of the approach for improving the delivery of poorly soluble drugs.

Conclusions:

  • Polymer-block-peptide conjugates offer a versatile platform for solubilizing and controlling the release of hydrophobic drugs.
  • The developed strategy is adaptable for various poorly soluble drugs and alternative cleavage mechanisms.
  • This approach holds significant promise for advancing drug delivery technologies.